The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia

• Published in: Journal of hematology and oncology 2017-02, Vol.10 (1), p.44-44, Article 44
• Main Authors: Qin, Ya-Zhen, Wang, Yu, Xu, Lan-Ping, Zhang, Xiao-Hui, Chen, Huan, Han, Wei, Chen, Yu-Hong, Wang, Feng-Rong, Wang, Jing-Zhi, Chen, Yao, Mo, Xiao-Dong, Zhao, Xiao-Su, Chang, Ying-Jun, Liu, Kai-Yan, Huang, Xiao-Jun
• Format: Article
• Language: English
• Subjects: Acute myelocytic leukemia; Acute myeloid leukemia; Adolescent; Adult; Allogeneic hematopoietic stem cell transplantation; Allografts; Analysis; Care and treatment; Chemotherapy; Child; Child, Preschool; Chromosomes, Human, Pair 21 - genetics; Chromosomes, Human, Pair 21 - ultrastructure; Chromosomes, Human, Pair 8 - genetics; Chromosomes, Human, Pair 8 - ultrastructure; Core Binding Factor Alpha 2 Subunit - biosynthesis; Core Binding Factor Alpha 2 Subunit - genetics; Donor lymphocyte infusion; Female; Follow-Up Studies; Gene Expression Regulation, Leukemic; Graft versus host disease; Hematology; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - metabolism; Leukemia, Myeloid, Acute - therapy; Male; Medical prognosis; Middle Aged; Neoplasm, Residual; Oncogene Proteins, Fusion - biosynthesis; Oncogene Proteins, Fusion - genetics; Oncology; Patients; Recurrence; Recurrence (Disease); Relapse; RNA, Messenger - biosynthesis; RNA, Messenger - genetics; RNA, Neoplasm - biosynthesis; RNA, Neoplasm - genetics; RUNX1 Translocation Partner 1 Protein - biosynthesis; RUNX1 Translocation Partner 1 Protein - genetics; RUNX1-RUNX1T1 transcript levels; Stem cell transplantation; Stem cells; Translocation, Genetic; Young Adult
• ISSN: 1756-8722; 1756-8722
• DOI: 10.1186/s13045-017-0414-2

The optimal monitoring schedules and cutoff minimal residual disease (MRD) levels for the accurate prediction of relapse at all time points after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remain unclear in patients with t(8;21) acute myeloid leukemia (AML). RUNX1-RUNX1T1 transcript levels were measured in bone marrow samples collected from 208 patients at scheduled time points after transplantation (1530 samples in total). A total of 92.3% of the requested samples were collected, and 74.0% of patients had complete sample collection. The 1-, 3-, and 6-month RUNX1-RUNX1T1 transcript levels could significantly discriminate between continuous complete remission and a hematologic relapse at 1.5-3, 4-6, and 7-12 months but not at >3, >6, and >12 months, respectively. Over 90% of the 175 patients who were in continuous complete remission had a ≥3-log reduction in RUNX1-RUNX1T1 transcript levels from the time of diagnosis at each time point after transplantation and a ≥4-log reduction at ≥12 months. A